PCI The Journeys Within

Current Edition

Frankfurt 2027 – 12/10/26
ramusmedical
news

Boehringer Ingelheim (Canada) Ltd. and IBM Canada announce first of its kind collaboration to integrate blockchain technology into clinical trials

Boehringer Ingelheim (Canada) Ltd. and IBM Canada announced at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando, Florida, the...
Continue Reading →
news

Use of clinical apps significantly improves quality of cardiovascular care

A pilot program using several clinical decision support tools in the outpatient setting to treat and educate stable ischemic heart disease patients has shown succes...
Continue Reading →
news

Ochsner Health System and Pfizer partner to develop innovative models for clinical trials

NEW ORLEANS & Ochsner Health System, Louisiana's largest non-profit academic healthcare system, and Pfizer Inc (NYSE:PFE) have entered into a multi-year strateg...
Continue Reading →
Europe

Orion’s and Bayer’s darolutamide shows substantial efficacy and a favourable safety profile in the treatment of prostate cancer in the ARAMIS trial

American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2019: Orion's and Bayer's darolutamide plus androgen deprivation therapy (A...
Continue Reading →
Europe

New Clinerion And Citeline Partnership Simplifies and Strengthens Matchmaking Between Clinical Researchers and Qualified Patients

Collaboration between two companies leads to more informed decisions for clinical researchers, grounded in real-world evidence. Citeline, part of the Informa Pharm...
Continue Reading →
Europe

Our brains indicate how well depression will respond to treatment

(Vienna, 19 February 2019) Working with international partners, a MedUni Vienna research group has shown that imaging techniques carried out prior to treatment indic...
Continue Reading →
Europe

AlzProtect, on Track for a Phase 2 Entry in 2019, for its Drug Candidate AZP2006

LILLE, France, February 20, 2019 --AlzProtect, a biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer's disease and Progressi...
Continue Reading →
news

Despite Phase III failure, Gilead’s selonsertib may still have place in NASH combination therapy strategy, says GlobalData

Despite its failure in the Phase III STELLAR-4 trial, Gilead Sciences’ lead non-alcoholic steatohepatitis (NASH) drug candidate, selonsertib, may still have a pla...
Continue Reading →
Asia Pacific

Owlstone Medical Partners with Shanghai Renji Hospital to Pioneer Breath Biopsy Lung Cancer Trial in China

Cambridge, UK, and Shanghai, China, February 20 2019:  Owlstone Medical Ltd., a global diagnostics company developing a breathalyzer for applications in ea...
Continue Reading →
Europe

Merck plans trio of Phase 3 Keytruda studies in prostate cancer

Merck & Co. said Thursday it plans to launch three pivotal Phase 3 studies testing different combination therapies involving its blockbuster immunotherapy Keytru...
Continue Reading →
Quotient